Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.89 USD | +0.13% | -0.25% | +73.63% |
05-09 | Larimar Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Zafgen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.63% | 503M | |
+7.60% | 111B | |
+11.36% | 106B | |
-12.40% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.95% | 16.81B | |
+38.07% | 12.54B | |
-24.33% | 8.09B |
- Stock Market
- Equities
- LRMR Stock
- News Larimar Therapeutics, Inc.
- Larimar Therapeutics : JMP Securities Adjusts Price Target on Larimar Therapeutics to $30 From $43, Maintains Market Outperform Rating